Cholestasis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Hepatic nuclear receptors, VDR, HNF4α, RXRα and RARα, were induced (approximately 2.0-fold, (p<0.05) whereas FXR levels were markedly reduced to 44% of control, (p<0.05) in human obstructive cholestasis.
|
25798860 |
2015 |
Cholestasis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In vivo, FXR knockout could significantly abrogate cholestasis induced FGF21 expression.
|
27003131 |
2016 |
Cholestasis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression of FXR target genes in the liver and intestine of cholestasis model rats was repressed.
|
30373117 |
2018 |
Cholestasis
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
These results indicate that expression of Ostalpha and Ostbeta are highly regulated in response to cholestasis and that this response is dependent on the FXR bile acid receptor.
|
16423920 |
2006 |
Cholestasis
|
0.600 |
Therapeutic
|
disease |
RGD |
Exploration of Hepatoprotective Effect of Gentiopicroside on Alpha-Naphthylisothiocyanate-Induced Cholestatic Liver Injury in Rats by Comprehensive Proteomic and Metabolomic Signatures.
|
30223280 |
2018 |
Cholestasis
|
0.600 |
Therapeutic
|
disease |
RGD |
Effects of corilagin on alleviating cholestasis via farnesoid X receptor-associated pathways in vitro and in vivo.
|
29235094 |
2018 |
Cholestasis
|
0.600 |
Therapeutic
|
disease |
RGD |
Role of AMP-activated protein kinase α1 in 17α-ethinylestradiol-induced cholestasis in rats.
|
27090119 |
2017 |
Cholestasis
|
0.600 |
Therapeutic
|
disease |
RGD |
Taken together, 18b-GA confers hepatoprotection against ANIT-induced cholestasis by activating FXR through Sirt1, which promotes gene expression of the efflux transporter, and consequently attenuates dysregulation of bile acid homeostasis in hepatocyte compartments.
|
30061734 |
2018 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Targeting FXR with small molecules has been exploited to treat lipid-related disorders and diseases such as cholestasis, gallstones and hepatic disorders.
|
30393515 |
2018 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
At early-stage cholestasis, most canalicular transporters and sinusoidal uptake transporters were downregulated, including bile salt export pump (BSEP, ABCB11), multidrug resistant protein 3 (MDR3, ABCB4), multidrug-resistant associated protein 2 (MRP2, ABCC2), sodium-dependent taurocholate cotransporting polypeptide (NTCP, SLC10A1), organic anion transporter (OATP, SLCO1A2), and nuclear receptor farnesoid X receptor (FXR, NR1H4).
|
18327154 |
2008 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Modulation of farnesoid X receptor results in post-translational modification of poly (ADP-ribose) polymerase 1 in the liver.
|
23178280 |
2013 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Despite the significant number of patent applications claiming steroidal and non-steroidal FXR agonists, several questions on their therapeutic potential in cholestasis and NASH remain open leaving a space for the development of novel compounds.
|
29649907 |
2018 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Pathways for SUMOylation were significantly altered during obstructive cholestasis with differential Sumo1 recruitment to the promoters of FXR target genes.
|
23546875 |
2013 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The findings revealed that SRT1720 treatment increased FXR and Nrf2 gene expressions to shield against hepatotoxicity and cholestasis induced by ANIT.
|
28553227 |
2017 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cholestasis activates bile acid receptor farnesoid X receptor (FXR) and subsequently enhances hepatic expression of small heterodimer partner (SHP).
|
25943116 |
2015 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Clinical features of severe, persistent NR1H4-related cholestasis include neonatal onset with rapid progression to end-stage liver disease, vitamin K-independent coagulopathy, low-to-normal serum gamma-glutamyl transferase activity, elevated serum alpha-fetoprotein and undetectable liver bile salt export pump (ABCB11) expression.
|
26888176 |
2016 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Modulation of transport and metabolism of bile acids and bilirubin by chlorogenic acid against hepatotoxicity and cholestasis in bile duct ligation rats: involvement of SIRT1-mediated deacetylation of FXR and PGC-1α.
|
29360226 |
2018 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The regulation about MDR3 mediated by FXR or PPARα in cholestasis is clear, but the mechanism through miRNA is hardly reported.
|
30964181 |
2019 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Organic anion transporting polypeptide 1a1 null mice are sensitive to cholestatic liver injury.
|
22461449 |
2012 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this context, therapeutic approaches including new hydrophilic BA such as the conjugation-resistant nor- ursodeoxycholic acid, nuclear receptors (FXR, PPAR-alpha) agonists, FGF19 analogues, inhibitors of the apical sodium-dependent bile acid transporter [ASBT] and modulators of the inflammatory cascade triggered by BAs are being studied as novel treatments of cholestasis.
|
29080340 |
2017 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
These FXR complexes provide direct insights into the design of therapeutic bile acids for treatment of hyperlipidemia and cholestasis.
|
12718893 |
2003 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this context, therapeutic approaches including the use of new hydrophilic BA such as the conjugation-resistant nor- ursodeoxycholic acid, nuclear receptor (FXR, PPAR-alpha) agonists, FGF19 analogues, inhibitors of the apical sodium-depend bile acid transporter (ASBT) and modulators of the inflammatory cascade triggered by BA are being studied as novel treatments of cholestasis.
|
31196636 |
2017 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
RGD |
The ileum-liver Farnesoid X Receptor signaling axis mediates the compensatory mechanism of 17α-ethynylestradiol-induced cholestasis via increasing hepatic biosynthesis of chenodeoxycholic acids in rats.
|
30077711 |
2018 |
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The coactivators attracted to promoters of FXR target genes and epigenetic modifications that occur after ligand binding to FXR have not been completely defined, and it is unknown whether these processes are disrupted during cholestasis.
|
21330447 |
2011 |
Cholestasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This suggests that a NR1H4 mutation is not or rarely involved in hepatocellular cholestasis of unknown cause.
|
23142591 |
2012 |